INMED PHARMACEUTICALS INC. Adjustments to Additional Paid in Capital, Other
INMED PHARMACEUTICALS INC. (INM) reported Adjustments to Additional Paid in Capital, Other of $6.05 million for the 12-month period ending 2021-06-30, per its 10-K filed 2022-09-23.
Discontinued › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalOther · last filed 2022-09-23
- INMED PHARMACEUTICALS INC. adjustments to additional paid in capital, other for fiscal 2021 was $6.05M.
| Period end | Adjustments to Additional Paid in Capital, Other 6 month | Adjustments to Additional Paid in Capital, Other 12 month |
|---|---|---|
| 2021-06-30 | $6.05M 10-K · filed 2022-09-23 | |
| 2020-12-31 | $6.05M 10-Q · filed 2022-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |